FTB Maps
Quantitative perfusion biomarker distinguishing high-grade brain tumor from non-tumor on a voxel-wise basis
Software · OtherCompany source
Company profile
About IMAGING BIOMETRICS
Imaging Biometrics is a medical imaging software company specializing in advanced quantitative analysis solutions for neuro-oncology. With over 30 years of focused research backing their technology, the company develops automated software that helps clinicians accurately characterize brain tumors and distinguish tumor from treatment effects. Their flagship products include IB Neuro, an exclusive MRI perfusion platform that generates quantitative relative cerebral blood volume (rCBV) maps; IB Delta T1 Maps, which identify true regions of contrast enhancement while eliminating confounding factors like post-surgical blood products; FTB Maps, a perfusion-based biomarker that distinguishes high-grade brain tumor from non-tumor tissue; and IB Nimble for rapid analysis. The company's solutions are trusted by leading brain tumor centers and have been validated in groundbreaking multi-center studies. Their technology addresses critical clinical challenges such as assessing residual enhancing tumor after surgery, differentiating tumor recurrence from treatment effects, guiding biopsy procedures, and monitoring treatment response. Imaging Biometrics serves radiologists, neurosurgeons, radiation oncologists, and neuro-oncologists at health systems and research institutions. The company's mission is to help clinicians extract maximum meaning from medical imaging studies, with patient care as the highest priority. Their solutions integrate with PACS systems and are compatible with both MRI and CT imaging modalities.
Company description IMAGING BIOMETRICS official website
Primary marketMedical Imaging & Radiology
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at IMAGING BIOMETRICS?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Brain tumors
- Glioblastoma (GBM)
- High-grade glioma
- Metastatic brain tumors
- Recurrent high-grade glioma
- Sellar lesions
Who it serves
- Academic Medical Centers
- Brain Tumor Centers
- Health Systems
- Research Institutions
Deployment & integration
Cloud Saas · Other deployment with recorded integration context.
Recorded integration context: PACS.
Geographic context
MarketsSwitzerland · United States
Company sourceOfficial website
Company milestones
Platform expansion
Expanded Access Program launched for IB Nimble. Used for image-guided surgical planning and anticipated use for radiation therapy planning.
Partnerships
Recorded partners
- Froedtert Memorial Lutheran Hospital
- Inselspital Bern University Hospital
- Medical College of Wisconsin
- Rhode Island Hospital
- Southwest Neuro-Imaging Ltd
- University of Wisconsin Hospitals and Clinics
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
IB Delta T1 Maps
Quantitative Delta T1 maps highlighting subtle contrast enhancements while ignoring blood products
Software · OtherCompany source
IB Diffusion
MR diffusion analysis generating ADC maps and advanced diffusion parameters
Software · OtherCompany source
IB Neuro
Exclusive MRI perfusion platform generating quantitative relative cerebral blood volume (rCBV) maps
Software · OtherCompany source
IB Nimble
Secure multi-disciplinary collaboration platform for treatment planning anytime, anywhere
Platform · Cloud SaaSCompany source
IB Rad Tech
Intelligent imaging workflow automation wizard simplifying complex imaging tasks
Software · OtherCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Integrated molecular and multiparametric MRI mapping of high-grade glioma identifies regional biologic signatures.Nature communications · Sep 28, 2023
Diverse types of expertise in facial recognition.Scientific reports · Jul 14, 2023
A cross-sectional study to test equivalence of low- versus intermediate-flip angle dynamic susceptibility contrast MRI measures of relative cerebral blood volume in patients with high-grade gliomas at 1.5 Tesla field strength.Frontiers in oncology · Jan 1, 2023
Multiinstitutional Evaluation of the Liver Surface Nodularity Score on CT for Staging Liver Fibrosis and Predicting Liver-Related Events in Patients With Hepatitis C.AJR. American journal of roentgenology · May 1, 2022
Can quantitative analysis of multi-parametric MRI independently predict failure of focal salvage HIFU therapy in men with radio-recurrent prostate cancer?Urologic oncology · Dec 1, 2021
Multisite Concordance of DSC-MRI Analysis for Brain Tumors: Results of a National Cancer Institute Quantitative Imaging Network Collaborative Project.AJNR. American journal of neuroradiology · Jun 1, 2018
Clinical validation
Clinical-trial records
Expanded Access to Gallium Maltolate (GaM)NCT06404034 · Sponsor · AVAILABLE
Pre-Radiation Chemotherapy for Newly Diagnosed High-Grade Glioma.NCT07439172 · Sponsor · NOT YET RECRUITING
Regulatory
Regulatory records
IB NEURO, VERSION 1.0K080762 · 510k · May 15, 2008
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
Accuracy in differentiating tumor types and predicting tumor grades
IB Neuro shown to far exceed accuracy and repeatability over other perfusion methods
Distinguishing post-treatment effects from tumor recurrence
Clinical utility demonstrated for treatment surveillance
50% reduction in gadolinium-based contrast agent
Proven reliable for both 1.5T and 3T MRI scanners
Correlation of FTB percentage to Overall Survival (OS)
Preliminary studies conducted by some groups
Inselspital, Bern University Hospital
Using dT1 method for assessing residual enhancing tumor after surgery, differentiating sellar lesions, and evaluating subtle enhancement in complex cases
Improved reliability in clinically relevant situations through standardization and high-quality quantifiable images
Medical College of Wisconsin & Froedtert Memorial Lutheran Hospital
Using IB products for image-guided surgical planning, radiation therapy planning, and routine perfusion scans and delta T1 maps for brain tumor analysis
Speed and PACS compatibility appreciated; products now routinely ordered by Neurosurgeons, Radiation Oncologists and Neuro-Oncologists
Rhode Island Hospital
Using IB Neuro plugin for brain tumor analysis and follow-up with normalized CBV maps overlayed on contrast enhanced or FLAIR images
Southwest Neuro-Imaging Ltd
Using Delta T1 and rCBV maps to guide therapeutic and surgical management of glioma patients when new areas of enhancement are identified
University of Wisconsin Hospitals and Clinics
Using IB Neuro and other plugins for nuclear medicine and neuroradiology applications
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
No active leadership profiles are currently listed.
06 · Company updates
Updates from IMAGING BIOMETRICS
Recent articles published on IMAGING BIOMETRICS's official website.
No Company updates are currently listed.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Medical Imaging & Radiology
Companies that apply AI to analyze medical images for diagnostic purposes, workflow optimization, or clinical decision support. Covers general radiology (X-rays, CT scans, MRIs, ultrasounds) across multiple organ systems, as well as specialized imaging in ophthalmology and dermatology.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.